FDA Adds New Warning To GLP-1 Drugs

WASHINGTON (AP) — The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic. FDA regulators on Monday said the warning information will be added to all GLP-1 drugs, the blockbuster medications whose popularity has exploded in recent years. The new language warns doctors of a rare eye condition that can cause loss of vision. The agency says the problem can be permanent and is not fully understood. The FDA says the issue has been reported with all GLP-1 drugs on the market, though it occurs in only a tiny fraction of patients.